(Q26858779)

main subject

cell surface receptor

1 reference

biomedical investigative technique

31 July 2019

1 reference

19 September 2019

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

15 December 2019

1 reference

3

0 references

Paolo Antonio Ascierto

series ordinal

1

object named as

Paolo A Ascierto

1 reference

2

Francesco M Marincola

1 reference

Journal of Translational Medicine

language of work or name

1 reference

13 November 2011

10 references

18 June 2019

19 June 2019

31 July 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

17 October 2022

10 references

18 June 2019

19 June 2019

31 July 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

17 October 2022

9

1 reference

page(s)

196

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

9 references

18 June 2019

19 June 2019

31 July 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

17 October 2022

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Melanoma: a model for testing new agents in combination therapies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262765

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

28 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-196

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-196

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-196

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-196

21 January 2018

Identifiers

DOI

10.1186/1479-5876-9-196

1 reference

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1479-5876-9-196

1 reference

PubMed publication ID

22077981

1 reference